Risk factors
Avalo Therapeutics (AVTX) risk factors
Item 1A of every Avalo Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks23 new15 dropped32 reworded
Avalo Therapeutics highlights heavy concentration on lead candidate abdakibart (AVTX-009). Financial runway depends on cash reserves dropping to $98.3 million. Regulatory risks emphasize reliance on third-party CROs and potential government agency slowdowns.
Filed Mar 23, 2026 - FY2024 10-K risk factors63 risks
Avalo Therapeutics focuses heavily on developing its lead biologic asset AVTX-009 for hidradenitis suppurativa.
Filed Mar 20, 2025